Nektar Therapeutics (NKTR) News
Filter NKTR News Items
NKTR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NKTR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NKTR News From Around the Web
Below are the latest news stories about NEKTAR THERAPEUTICS that investors may wish to consider to help them evaluate NKTR as an investment opportunity.
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic DermatitisNektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. |
Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media?We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other best penny stocks to buy according to the media. Small-Cap Stocks Outlook for 2025 On December 24, Global Advisors’ […] |
Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownershipKey Insights Given the large stake in the stock by institutions, Nektar Therapeutics' stock price might be vulnerable... |
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH MeetingNektar Therapeutics (Nasdaq: NKTR) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) at the 66th ASH Annual Meeting and Exposition in San Diego, California. |
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) ConvergenceNektar Therapeutics (Nasdaq: NKTR) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR) conference, being held in Washington, D.C. from November 14-19, 2024. |
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price TargetsNektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers with... |
Nektar Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNektar Therapeutics ( NASDAQ:NKTR ) Third Quarter 2024 Results Key Financial Results Revenue: US$24.1m (flat on 3Q... |
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in FocusNKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year. |
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial OutlookNektar Therapeutics (NKTR) extends its cash runway into 2026 with strategic divestitures, despite ongoing financial challenges and litigation uncertainties. |
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue EstimatesNektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |